omegaConotoxin

Omegaconotoxin, more commonly written as omega-conotoxin, refers to a family of peptide neurotoxins produced by predatory cone snails of the genus Conus. These small, cysteine-rich peptides are part of the venom used by cone snails to immobilize prey. The best-known member of this family is omega-conotoxin MVIIA, from Conus magus, which underlies the clinically developed drug ziconotide.

Mechanistically, omega-conotoxins selectively block N-type voltage-gated calcium channels (CaV2.2) on presynaptic nerve terminals. By inhibiting calcium influx, they reduce the release of neurotransmitters such as glutamate and substance P, thereby dampening the transmission of pain signals in the spinal cord and central nervous system. This mode of action makes them powerful analgesics in experimental and clinical contexts.

Chemically, omega-conotoxins are short peptides, typically in the 20–30 amino acid range, with multiple disulfide bonds that stabilize their structure. The specific amino acid sequences and disulfide arrangements determine their potency and selectivity for CaV2.2 channels, leading to a range of pharmacological profiles across different conotoxin variants.

Clinical relevance, particularly for MVIIA (ziconotide), centers on intrathecal use for severe chronic pain. Ziconotide is a synthetic form of MVIIA approved for intrathecal administration, as oral delivery is ineffective and the therapeutic window is narrow. Patients may experience significant adverse effects, including dizziness, confusion, and psychiatric symptoms, necessitating careful dose titration and monitoring.

Beyond clinical use, omega-conotoxins serve as valuable pharmacological tools for studying pain pathways and as templates for developing non-opioid analgesics and targeted delivery strategies.